According to a July 24 news release from biopharmaceutical company Concentric Analgesics, the patients in the group receiving the highest dose (0.30 mg/ml) of vocacacapsaicin saw a 33% reduction in pain at rest by the fifth day of the phase 2 trial, and 37% saw a reduction in pain at rest by the eighth day.
In addition, the trial found that 100% of the vocacacapsaicin group stopped opioid use for pain relief by the fifth day of the study, while 16% those in the control group still required opioid analgesia on the same day of the study.
The drug triggers the TRPV1 receptor on pain-specific nerves, which can provide long-term pain relief without causing the sensory numbness or motor weakness like some local anesthetics, the release said. As a non-opioid, vocacapsaicin does not pose the same addictive risk as opioid pain relievers.
“This is the first demonstration of a single intraoperative injection leading to earlier cessation of opioids after surgery,” Steven Shafer, MD, an adviser to Concentric who led the trial and a former Stanford (Calif.) University professor, said in the release. “By targeting TRPV1 receptors, vocacapsaicin eclipses the duration of pain relief possible from local anesthetic formulations.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
